Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

57%

4 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 2

2(28.6%)

Phase 1

1(14.3%)

7Total

Phase 3(4)

Phase 2(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT00414128Phase 2Completed

Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis

Role: collaborator

NCT00324506Phase 2Completed

Safety and Efficacy of Cellcept and Avonex as Combination Treatment in Multiple Sclerosis

Role: collaborator

NCT00377637Phase 3Completed

A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.

Role: collaborator

NCT00683930Phase 3Completed

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)

Role: collaborator

NCT00433186Phase 1Completed

Mycophenolate Mofetil in Systemic Sclerosis

Role: collaborator

NCT00683969Phase 3Completed

A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis

Role: collaborator

NCT00408213Phase 3Completed

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Role: collaborator

All 7 trials loaded